The following post was written by Jack Harley, MSc We all want to live a long and healthy life, but as we age, various forms of biological damage result in increased susceptibility for disease. As a result, longevity supplements are becoming increasingly popular as people look for ways to improve their health and extend their ...

The Longevity Biotech Fellowship (LBF) – a non-profit community aiming to bring people together to help progress the revolutionary field of longevity – is back, opening its doors to a new cohort of entrepreneurs, students, and investors. The upcoming program that’s set to launch in January 2023 represents LBF’s third cohort since its inception. Applications ...

NMN supplements, a market estimated to be worth $280.2 million this year, just got a no-go from the FDA, curbing many “anti-aging” supplement providers and longevity enthusiasts from interacting with one of the most popular longevity supplements on the market. While the news has stirred up a bit of drama and finger-pointing, which we’ll eventually ...

In June of this year, a new company was teased at the 4th Longevity Therapeutics Summit that had researchers and investors alike buzzing. Presented by none other than Dr. Matt Kaeberlein, this new company – named Ora Biomedical – focused on high-throughput drug screening using robotics and AI. But although the company sounded interesting and ...

Hevolution Foundation, the behemoth non-profit with an annual $1 billion budget, this week released a new grant program to fund aging-related research that has been overlooked. The pilot program – Hevolution Foundation – Advancing Geroscience Efforts (HF-AGE) – plans to fund ten longevity projects with up to $5 million in 2022.  The goal of HF-AGE ...

  October’s Longevity Funding Roundup: $376M Raised Across 9 Funding Rounds PreComb Therapeutics, a company developing an evidence-based therapy prediction for cancer drug discovery and therapy guidance, closes 1.3 million CHF Pre-Series A Round led by LongeVC and Kinled Form Bio, a spin-out from Colossal Biosciences that offers an advanced, comprehensive software platform that replaces ...

The field of longevity only continues to grow. With funding rounds and research efforts ramping up, slowly but surely, the industry is beginning to detach itself from the broad world of biotech. What’s not so obvious, however, is which companies and founders are blazing the path forward. To help bridge this gap, Spannr will be ...

Brian Armstrong, CEO of one of the world’s largest crypto exchanges, Coinbase (COIN), announced on Twitter this week his intention to sell 2% of his personal company holdings to further fund scientific research, including his longevity company NewLimit. Armstrong on Friday tweeted: “I’m passionate about accelerating science and tech to help solve some of the ...

From the earliest moments of consciousness, humankind looked to the stars for answers. Much as our forefathers used astrotheology as a predictive tool, today, we are harnessing science in conjunction with space to see what’s happening beneath the hood of our bodies. While the methods have advanced, our core intent hasn’t. Not satisfied with Earthly ...

In June, Spannr reported that San Diego-based Human Longevity had agreed to go public in a SPAC transaction at an implied valuation of $1 billion. The company was all but set to combine with the $345 million blank check company, Freedom Acquisition Corp (FACT). As we reported at the time: “With the SPAC and biotech market facing significant headwinds ...